F&M’s Annual Ohio and Indiana Golf Classics Raise $53,000 for Local Charities
ARCHBOLD, OHIO, Sept. 27, 2024 (GLOBE NEWSWIRE) — F&M Bank (“F&M”), an Archbold, Ohio-based bank owned by Farmers & Merchants […]
Focus on AI Water, Completed Strategic Reorganization – Viomi Investor Day
Guangdong, China, Sept. 27, 2024 (GLOBE NEWSWIRE) — On September 26, 2024, Viomi Technology Co., Ltd (NASDAQ: VIOT) held its […]
Weekly Report (September 20-26, 2024) Third Tranche of Stellantis 2024 Share Buyback Program
Weekly Report (September 20-26, 2024) Third Tranche of Stellantis 2024 Share Buyback Program AMSTERDAM, September 27, 2024 – Stellantis N.V. (“Stellantis” […]
WTW expands Asia Client Division – CRB N.A. with new China Client Division Leader for North America
NEW YORK, Sept. 27, 2024 (GLOBE NEWSWIRE) — WTW (NASDAQ: WTW), a leading global advisory, broking, and solutions company, today […]
Horizon Bancorp, Inc. Announces Conference Call to Review Third Quarter 2024 Results on October 24
MICHIGAN CITY, Ind., Sept. 27, 2024 (GLOBE NEWSWIRE) — (NASDAQ GS: HBNC) – Horizon Bancorp, Inc. (“Horizon” or the “Company”) […]
Cytokinetics Presents Additional Data from SEQUOIA-HCM at the HCMS Scientific Sessions
SOUTH SAN FRANCISCO, Calif., Sept. 27, 2024 (GLOBE NEWSWIRE) — Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that additional data from […]
Oil-Dri Named One of the Top 100 Finalists for the 23rd Annual Chicago Innovation Awards
CHICAGO, Sept. 27, 2024 (GLOBE NEWSWIRE) — Out of 350 nominees, Oil-Dri Corporation of America (NYSE: ODC), headquartered in Chicago, […]
TSX News -
Knight Therapeutics Inc. places No. 397 on The Globe and Mail’s sixth annual ranking of Canada’s Top Growing Companies
MONTREAL, Sept. 27, 2024 (GLOBE NEWSWIRE) — Knight Therapeutics Inc. (TSX:GUD) (“Knight” or “the Company”) is pleased to announce it […]
Edible Garden Announces Pricing of $5.65 Million Public Offering
BELVIDERE, N.J., Sept. 27, 2024 (GLOBE NEWSWIRE) — Edible Garden AG Incorporated (“Edible Garden” or the “Company”) (Nasdaq: EDBL, EDBLW), […]
Dupixent® (dupilumab) Approved in the U.S. as the First-ever Biologic Medicine for Patients with COPD
Dupixent is indicated for the approximately 300,000 adults in the U.S. with inadequately controlled chronic obstructive pulmonary disease (COPD) and an eosinophilic phenotype [...]
